October 11th, 2007. Role of DNA microarrays in the diagnosis of pleural exudates: a feasibility study
Conclusions: Gene expression study of cells from pleural fluid is feasible but remains difficult, essentially in relationship with RNA weakness.
October 6th, 2007. The value of calretinin and cytokeratin 5/6 as markers for mesothelioma in cell block preparations of serous effusions
Conclusions: The results confirm that calretinin and CK 5/6 are useful markers for mesothelioma in effusion specimens. CK5/6 staining may be less useful for peritoneal fluid specimens where metastatic adenocarcinomas may be more likely to express the antigen. Further study of ascitic/peritoneal specimens is warranted. However, positive staining, particularly for both antigens, is highly indicative of a mesothelial origin for cells. The two markers make a useful addition to EMA and the panel of adenocarcinoma markers routinely applied to effusion specimens.
September 4th, 2007. Clinical utility of thoracoscopy under local anesthesia
In case of the pneumothorax, treatment with bulla looping or cauterization may be possible, but we do not treat pneumothorax with medical thoracoscopy because it is impossible to approach and find air leaks of lesions located in or near blind spots such as the apex or mediastinal part In case of acute emphysema, it is important to release adhesions and perform effective drainage using thoracoscopy as soon as possible since deposition of fibrin tends to form quickly compartments that make drainage difficult. Since medical thoracoscopy under local anesthesia is rapid, easy, safe, and well-tolerated procedure with an excellent diagnostic yield, it is recommended as a diagnostic procedure for cases with pleural diseases.
September 4th, 2007. Disorders of hemostatic system in patients with malignant disease, especially in view of venous thromboembolism
Conclusion: Active cancer is often associated with hypercoagulable state, which pertubs the hemostatic balance between anticoagulant and procoagulant forces, creating a prothrombotic state. The interaction between tumor cells and host cells involves direct cell-cell interaction or indirect mechanism by cytokine release. Hypercoagulable state in patients with malignant disease may result in the occurence of various clinically identifiable hemostatic system disorders: the most frequent one is venous thromboembolism (so-called secondary thrombosis). In cases of idiopathic venous thromboembolism, it is recommended to carry out specific clinical check-up to prove or to preclude asymptomatic malignant diseases.
Conclusions: The findings in our patients, combined with the literature review, suggest that: (1) the most common clinical presentation of ONJ is pain and exposed bone of the mandible or maxilla; (2) for patients who develop ONJ, conservative, non-surgical treatment is strongly recommended; (3) clinical dental examination and a panoramic jaw radiograph should be performed before patients begin bisphosphonate therapy; (4) dental treatment and other oral procedures should be completed before initiating bisphosphonate therapy; (5) patients should be informed and instructed on the importance of maintaining good oral hygiene and having regular dental assessment; and (6) the medical community needs to be aware of the association between bisphosphonate usage and ONJ so that unnecessary and harmful surgical procedures can be avoided.
August 19th, 2007. Flow cytometric immunophenotyping of cancer cells in effusion specimens: diagnostic and research applications
Our data suggest that FCM is an effective method for the characterization of cancer cells in clinical effusion specimens in both the diagnostic and research setting, and that this method is comparable to immunohistochemistry in terms of sensitivity and specificity, with the additional advantage of providing quantitative data. This review discusses previous work in this area and the future potential of this method in the characterization of tumor cells in serous effusions.
Conclusions: Intrapleural instillation of Ad.IFN-ß is a potentially useful approach for the generation of antitumor immune responses in MPM and MPE patients and should be investigated further for overall clinical efficacy.
July 26th, 2007. Dextran-based in situ cross-linked injectable hydrogels to prevent peritoneal adhesions
However, all cross-linked gels had very mild cytotoxicity. When applied in a rabbit sidewall defect-bowel abrasion model of adhesion formation, CMDX–CMC greatly reduced the formation of adhesions while CMDX–DX worsened them.
July 12th, 2007. Trousseau syndrome due to pleural mesothelioma
Conclusion: Attention should be paid to this syndrome when unexplained brain infarctions occur in patients with pleural mesothelioma.
July 4th, 2007. Constrictive pericarditis after left extrapleural pneumonectomy and radiotherapy for malignant mesothelioma
Our experience, combined with a review of the available literature, leads us to advise a low level of suspicion and early operation to relieve cardiac constriction. Furthermore, these complications emphasize the importance of trials such as the Mesothelioma and Radical Surgery (MARS) study.
June 23rd, 2007. Management of malignant pleural effusion
PET imaging could be of major interest in the diagnosis of mesothelioma and prognosis evaluation. Mesothelioma prognosis has recently been modified by the association of cisplatin with pemetrexed, a new antimetabolite agent, but mesothelioma remains seldom curable.
June 22nd, 2007. The Diagnostic Role of Claudins in Serous Effusions
Our data suggest that expression of claudin-3 or claudin-7 is specific for adenocarcinoma and rules out the diagnosis of cells as mesothelial and that absence of claudin-1 expression excludes ovarian carcinoma as the possible origin of metastatic adenocarcinoma. Claudins may, therefore, be of diagnostic value in effusion cytology.
June 1st, 2007. MN/CA9: a potential gene marker for detection of malignant cells in effusions
Our preliminary results suggest that MN/CA9 could be a potential marker for the detection of malignant cells in effusions. A large-scale study is needed to confirm these results.
May 15th, 2007. Diagnostic utility of D2-40 and podoplanin in effusion cell blocks
It is concluded that D2-40 and podoplanin are very useful markers for mesotheliomas. Since these markers are extremely helpful in differentiating epithelioid mesothelioma from metastatic adenocarcinoma, they shall be a valuable addition to the battery of markers used to differentiate the two entities.
Conclusions: SMRP measured on automated systems could be useful for the diagnosis of mesothelioma in routine clinical practice.
May 5th, 2007. Validity, reliability and clinical relevance of EORTC QLQ-C30 and LC13 in patients with chest malignancies in a palliative setting
Conclusion: The results support the validity and clinical relevance and of the EORTC questionnaire in a palliative setting.
May 3rd, 2007. Dyspnea With Slow-Growing Mass of the Left Hemithorax
SFTP is a rare neoplasm, and diagnosis is often difficult. Suspicion of SFTP should arise in the setting of a patient presenting with a paucity of symptoms (except in the case of an accompanying paraneoplastic syndrome), the absence of exposure to asbestos, and a large mass with sharp margins and encapsulation seen on a chest radiograph.
Conclusion: This study suggests that sequence-dependent administration of RAL (5FU/MTA/RAL), in combination with 5-FU/MTA, protects against MTA toxicity in human bone marrow while maintaining the maximum inhibitory effect of pemetrexed in breast cancer.
April 19th, 2007. Chemokine receptors are infrequently expressed in malignant and benign mesothelial cells
This finding suggests a major role for an autocrine chemokine pathway in leukocytes but not in MM cells. The increased monocyte infiltration and their higher chemokine receptor expression in MM effusions may have a tumor-promoting rather than tumor-inhibiting effect.
April 17th, 2007. A large abdominal wall mass as an initial manifestation of malignant mesothelioma
Despite further radiotherapy, the patient died of cardiac tamponade due to tumor invasion 38 months after the initial diagnosis. To the best of our knowledge, this is the first description of malignant mesothelioma presenting via initial invasion of the abdominal wall without changes in the thoracic space.
- Home
- About Mes-Line
- Categories
- Contact Us
- Glossary
- Processor
Article Categories
- Full Archive
- Type of Assessment:
- Case Study
- Causation
- Diagnosis & Differentiation
- Epidemiological
- General
- Staging
- Survival
- Symptoms & Symptom Management
- Treatment
- Angiogenesis
- Chemotherapy
- Bevacizumab (Avastatin)
- Carboplatin
- Cisplatin (Platinol ®)
- Coramsine
- Cyclophosphamide
- Cycloplatam
- Docetaxel (Taxotere)
- Doxorubicin
- Epirubicin (Ellence)
- Erlotinib (Tarceva®)
- Gemcitabine (Gemzar)
- Imatinib Mesylate (Gleevec/Glivec)
- Irinotecan
- melphalan
- mitomycin-C
- Oxaliplatin (Eloxatin)
- Oxaliplatine
- paclitaxel
- Pemetrexed (Alimta)
- Raltitrexed (Tomudex)
- Ranpirnase (Onconase)
- Selenite
- Sunitinib
- Taurolidine
- Vinorelbine
- Determining Efficacy
- EGFR
- Gene Therapy
- Immune-based Therapies
- Intraperitoneal Chemotherapy
- Intrapleural Chemotherapy
- Kinase Inhibitors
- New & Novel
- Photodynamic Therapy (PDT)
- pleurodesis
- Proteasome inhibitors
- Radiation
- Radiofrequency Ablation
- Signal Transduction Inhibitors
- Surgery
- Trimodality Therapy
- Type of Mesothelioma:
Annual Archives:
-
You are currently browsing the archives for the Symptoms & Symptom Management category.
